Unity Biotechnology focuses on developing medicines that target cellular senescence to treat age-related diseases. Senescent cells accumulate with age and contribute to tissue dysfunction and inflammation. The company's lead programs target conditions like osteoarthritis, ophthalmologic diseases, and pulmonary diseases. Unity went public in 2018 and represents the emerging field of aging and longevity therapeutics.
Unity Biotechnology has received investment from 1 venture capital firm.
Biotechnology company developing therapeutics to halt, slow, or reverse diseases of aging by targeting senescent cells.
Unity Biotechnology has received investment from ARCH Venture Partners. These venture capital firms and investors provide both capital and strategic support.
Unity Biotechnology has raised $305M in total funding, with their most recent round being a IPO. The company operates in the Biotech sector.
Unity Biotechnology was founded in 2011 and is headquartered in South San Francisco, California.
Unity Biotechnology operates in the Biotech sector. Biotechnology company developing therapeutics to halt, slow, or reverse diseases of aging by targeting senescent cells.
